This bill limits how many patents brand-name drug companies can use to block generic versions of biological drugs (biologics). It caps the number of patents a brand company can assert in lawsuits against generic manufacturers at 20, with no more than 10 being patents issued after a specified date. Courts may allow more patents only in specific cases, such as if the generic company fails to provide required information or if there are material changes to the product. The law applies to new applications submitted after enactment and aims to reduce patent-related delays for cheaper generic biologics.
S 652 requires social media influencers and healthcare providers to avoid false or misleading promotions of FDA-approved drugs on social media, including disclosing key safety information like side effects in a summary format similar to traditional drug ads. It makes these individuals liable for civil penalties if they knowingly or recklessly omit critical facts or fail to include required safety summaries. The bill also directs the FDA to issue new guidance on enforcement, monitor drug ads using AI, and conduct market surveillance on social media platforms. This affects influencers, healthcare providers, and drug manufacturers who pay for such promotions, with the FDA authorized to spend $15 million annually for enforcement.
The DTC Act of 2025 requires pharmaceutical companies to include a drug's list price (for a 30-day supply) in direct-to-consumer television and digital ads for prescription drugs covered by Medicare or Medicaid. It applies to ads for drugs costing $35 or more per 30-day supply, exempting lower-cost medications. Manufacturers must disclose the list price clearly by July 1, 2026, with penalties of up to $100,000 per violation for noncompliance. The bill aims to provide consumers with upfront pricing information to help them compare costs before filling prescriptions, particularly affecting drugs commonly advertised to Medicare beneficiaries.
This bill amends the Affordable Care Act to establish an annual out-of-pocket spending cap for prescription drug cost-sharing under health insurance plans. For 2027, it sets a $2,000 limit for self-only coverage and $4,000 for family coverage (twice the self-only amount). The cap adjusts annually based on premium changes, rounded to the nearest $50 increment. It directly affects ACA planholders with prescription drug coverage, limiting their yearly cost-sharing expenses for medications starting in 2027.
This bill requires the VA to provide telehealth services, mail-order pharmacy benefits, and mandatory beneficiary travel payments to veterans residing in the Freely Associated States (including Palau, the Marshall Islands, and Micronesia) within one year of enactment. It mandates quarterly reporting to Congress on implementation progress and associated costs. The law directly affects veterans in these Pacific Island nations by expanding access to critical healthcare and travel support services previously not uniformly guaranteed.
S 2658, the Medication Affordability and Patent Integrity Act, requires drug manufacturers to certify that patent information submitted to the FDA for new drug approvals matches what they provided to the U.S. Patent and Trademark Office (USPTO). It mandates that sponsors submit patent-related data to the USPTO and certify its accuracy, ensuring consistency between FDA and patent filings for drugs and biologics. The bill creates a new legal defense for generic drug makers in patent lawsuits if a brand-name company failed to disclose required patent information. This applies to new drug applications filed after the law's enactment, directly affecting pharmaceutical companies seeking FDA approval for new medications.
The PILLS Act creates tax credits to incentivize domestic production of generic drugs and biosimilars in the United States. It offers a production credit of 30% (35% for final drug products) of the value added to eligible components, with an additional domestic content bonus of up to 20% for components made with US-sourced materials. Companies can also claim a 25% investment credit for qualified facilities producing these drugs, phasing out for facilities beginning construction after 2028. The bill excludes foreign entities of concern from these benefits and requires documentation for domestic content claims. These provisions apply to FDA-approved generic drugs and biosimilars to increase domestic supply of essential medications.
The Drug Shortage Prevention Act of 2025 requires manufacturers of critical drugs - such as life-saving medications for emergencies, surgery, or serious conditions - to notify the federal government about potential supply disruptions. Manufacturers must report planned production halts at least six months in advance or sudden issues like demand spikes within 10 business days, including reasons and expected duration. The bill also mandates twice-yearly reports on drug supply chains, detailing active ingredient sources and suppliers. This aims to improve transparency and prevent shortages affecting patient access to essential medications.
The REMEDY Act (S 2620) modifies how generic drug manufacturers certify patents when seeking FDA approval. It requires drug companies to select one specific patent upfront as the "covered patent" for the 30-month delay period (which blocks generic competition), and they cannot change this selection later. This targets "evergreening" tactics where brand-name drug companies list multiple patents to extend monopolies. The bill directly affects pharmaceutical companies filing generic applications and the FDA's patent review process.
This bill requires private health insurance plans to cover insulin for people under age 26 without deductibles, capping out-of-pocket costs at $35 per 30-day supply or 25% of the negotiated price (whichever is lower). It mandates coverage of multiple insulin types and formulations (like rapid-acting, long-acting, and premixed) to ensure access to various treatment options. The rule applies to employer-sponsored plans, ACA marketplace plans, and similar coverage starting in 2026. It directly affects young adults (up to age 26) managing diabetes who rely on private insurance for insulin.
